Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Périssé, André R S ^a   Smeaton, Laura ^b   Chen, Yun ^b   La Rosa, Alberto ^c   Walawander, Ann ^d   Nair, Apsara ^d   Grinsztejn, Beatriz ^e   Santos, Breno ^f   Kanyama, Cecilia ^g   Hakim, James ^h   Nyirenda, Mulinda ⁱ   Kumarasamy, Nagalingeswaran ^j   Lalloo, Umesh G ^k   Flanigan, Timothy ^l   Campbell, Thomas B ^m   Hughes, Michael D ⁿ  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e Funda??o Oswaldo Cruz   (Brazil)

^f HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^g KAMUZU CENTRAL HOSPITAL   (Malawi)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

ⁱ UNIVERSITY OF MALAWI   (Malawi)

^j YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^k UNIVERSITY OF KWAZULU NATAL   (South Africa)

^l BROWN UNIVERSITY   (United States)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁿ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VIRAL LOAD;

EID: 84894288371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083643     Document Type: Article

References (24)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-9. (Pubitemid 36835816)
2. Sabin CA (2002) The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 16 Suppl 4: S61-8.
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR et al. (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-9.
4. Esposito A, Floridia M, d'Ettorre G, Pastori D, Fantauzzi A et al. (2011) Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infect Dis 11: 341.
5. Perez-Molina JA, Diaz-Menendez M, Plana MN, Zamora J, Lopez-Velez R et al. (2012) Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials. J Antimicrob Chemother 67: 312-21.
6. Aiuti F, Mezzaroma I (2006) Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 8: 88-97. (Pubitemid 44043557)
7. French MA, Price P, Stone SF (2004) Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-27. (Pubitemid 39095778)
8. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S et al. (2005) The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 6: 140-3. (Pubitemid 40425979)
9. Mocroft A, Sterne JA, Egger M, May M, Grabar S et al. (2009) Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48: 1138-51.
10. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-21. (Pubitemid 36548927)
11. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ (2010) The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PloS One 5: e15241.
12. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362: 697-706.
13. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S (2006) Survival rate and risk factors of mortality among HIV/tuberculosis- coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43: 42-6. (Pubitemid 44306486)
14. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E et al. (2009) Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 50: 148-52.
15. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365: 1482-91.
16. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed April 20 2013.
18. Lawn SD, Torok ME, Wood R (2011) Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 24: 34-42.
19. Zolopa A, Andersen J, Komarow L, Sanne I, Sanchez A et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One 4: e5575.
20. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL et al. (2012) Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 9: e1001290.
21. Westreich D, Fox MP, Van Rie A, Maskew M (2012) Prevalent tuberculosis and mortality among HAART initiators. AIDS 26: 770-3.
22. Dronda F, Sobrino-Vegas P, Hernandez-Novoa B, Caro-Murillo AM, Marta M et al. (2011) Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections. Curr HIV Res 9: 229-36.
23. Degu WA, Lindquist L, Aderaye G, Aklillu E, Wold AH et al. (2012) Randomized clinical trial to determine efficacy and safety of ART 1 week after TB theraphy in patients with CD4 counts <200 cells/ml. 19th Conference on Retrovirus and Opportunistic Infections. 5-8 March 2012, Seattle, USA. Paper #144.
24. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D et al. (2011) Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9: 446-69.